Literature DB >> 24866693

Complex molecular regulation of tyrosine hydroxylase.

Izel Tekin1, Robert Roskoski, Nurgul Carkaci-Salli, Kent E Vrana.   

Abstract

Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis, is strictly controlled by several interrelated regulatory mechanisms. Enzyme synthesis is controlled by epigenetic factors, transcription factors, and mRNA levels. Enzyme activity is regulated by end-product feedback inhibition. Phosphorylation of the enzyme is catalyzed by several protein kinases and dephosphorylation is mediated by two protein phosphatases that establish a sensitive process for regulating enzyme activity on a minute-to-minute basis. Interactions between tyrosine hydroxylase and other proteins introduce additional layers to the already tightly controlled production of catecholamines. Tyrosine hydroxylase degradation by the ubiquitin-proteasome coupled pathway represents yet another mechanism of regulation. Here, we revisit the myriad mechanisms that regulate tyrosine hydroxylase expression and activity and highlight their physiological importance in the control of catecholamine biosynthesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24866693     DOI: 10.1007/s00702-014-1238-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  288 in total

1.  Crystal structure of tyrosine hydroxylase at 2.3 A and its implications for inherited neurodegenerative diseases.

Authors:  K E Goodwill; C Sabatier; C Marks; R Raag; P F Fitzpatrick; R C Stevens
Journal:  Nat Struct Biol       Date:  1997-07

2.  Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression.

Authors:  Frank M J Jacobs; Susan van Erp; Annemarie J A van der Linden; Lars von Oerthel; J Peter H Burbach; Marten P Smidt
Journal:  Development       Date:  2009-01-14       Impact factor: 6.868

Review 3.  Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation.

Authors:  R E Zigmond; M A Schwarzschild; A R Rittenhouse
Journal:  Annu Rev Neurosci       Date:  1989       Impact factor: 12.449

4.  A novel basal promoter element is required for expression of the rat tyrosine hydroxylase gene.

Authors:  S Patankar; M Lazaroff; S O Yoon; D M Chikaraishi
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

5.  Mutation of regulatory serines of rat tyrosine hydroxylase to glutamate: effects on enzyme stability and activity.

Authors:  Montserrat Royo; Paul F Fitzpatrick; S Colette Daubner
Journal:  Arch Biochem Biophys       Date:  2005-02-15       Impact factor: 4.013

6.  Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells.

Authors:  Xiangmin Peng; Xiangmin M Peng; Roya Tehranian; Paula Dietrich; Leonidas Stefanis; Ruth G Perez
Journal:  J Cell Sci       Date:  2005-07-19       Impact factor: 5.285

7.  Chronic nicotine treatment leads to induction of tyrosine hydroxylase in locus ceruleus neurons: the role of transcriptional activation.

Authors:  Baoyong Sun; Xiqun Chen; Lu Xu; Carol Sterling; A William Tank
Journal:  Mol Pharmacol       Date:  2004-07-16       Impact factor: 4.436

8.  Differential regulation of human tyrosine hydroxylase isoforms 1 and 2 in situ: Isoform 2 is not phosphorylated at Ser35.

Authors:  Sarah L Gordon; Larisa Bobrovskaya; Peter R Dunkley; Phillip W Dickson
Journal:  Biochim Biophys Acta       Date:  2009-10-13

9.  Activity-dependent phosphorylation of tyrosine hydroxylase in dopaminergic neurons of the rat retina.

Authors:  Paul Witkovsky; Eleonora Veisenberger; John W Haycock; Abram Akopian; Antonio Garcia-Espana; Emanuel Meller
Journal:  J Neurosci       Date:  2004-04-28       Impact factor: 6.167

10.  Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development.

Authors:  Q Y Zhou; C J Quaife; R D Palmiter
Journal:  Nature       Date:  1995-04-13       Impact factor: 49.962

View more
  37 in total

1.  Investigation of the therapeutic potential of N-acetyl cysteine and the tools used to define nigrostriatal degeneration in vivo.

Authors:  Negin Nouraei; Lauren Zarger; Justin N Weilnau; Jimin Han; Daniel M Mason; Rehana K Leak
Journal:  Toxicol Appl Pharmacol       Date:  2016-02-12       Impact factor: 4.219

Review 2.  Autonomic regulation of T-lymphocytes: Implications in cardiovascular disease.

Authors:  Safwan K Elkhatib; Adam J Case
Journal:  Pharmacol Res       Date:  2019-06-06       Impact factor: 7.658

3.  Molecular interrogation of hypothalamic organization reveals distinct dopamine neuronal subtypes.

Authors:  Roman A Romanov; Amit Zeisel; Joanne Bakker; Fatima Girach; Arash Hellysaz; Raju Tomer; Alán Alpár; Jan Mulder; Frédéric Clotman; Erik Keimpema; Brian Hsueh; Ailey K Crow; Henrik Martens; Christian Schwindling; Daniela Calvigioni; Jaideep S Bains; Zoltán Máté; Gábor Szabó; Yuchio Yanagawa; Ming-Dong Zhang; Andre Rendeiro; Matthias Farlik; Mathias Uhlén; Peer Wulff; Christoph Bock; Christian Broberger; Karl Deisseroth; Tomas Hökfelt; Sten Linnarsson; Tamas L Horvath; Tibor Harkany
Journal:  Nat Neurosci       Date:  2016-12-19       Impact factor: 24.884

4.  Early Postnatal Manganese Exposure Reduces Rat Cortical and Striatal Biogenic Amine Activity in Adulthood.

Authors:  Stephen M Lasley; Casimir A Fornal; Shyamali Mandal; Barbara J Strupp; Stephane A Beaudin; Donald R Smith
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

5.  Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson's disease via mechanisms associated with increased protein kinase activity in the striatum.

Authors:  Neha Milind Chitre; Bo Jarrett Wood; Azizi Ray; Nader H Moniri; Kevin Sean Murnane
Journal:  Neuropharmacology       Date:  2020-01-27       Impact factor: 5.250

6.  Islet proteomics reveals genetic variation in dopamine production resulting in altered insulin secretion.

Authors:  Kelly A Mitok; Elyse C Freiberger; Kathryn L Schueler; Mary E Rabaglia; Donald S Stapleton; Nicholas W Kwiecien; Paige A Malec; Alexander S Hebert; Aimee T Broman; Robert T Kennedy; Mark P Keller; Joshua J Coon; Alan D Attie
Journal:  J Biol Chem       Date:  2018-03-01       Impact factor: 5.157

7.  Innervation of the medial prefrontal cortex by tyrosine hydroxylase immunoreactive fibers during adolescence in male and female rats.

Authors:  Jari Willing; Laura R Cortes; Joseph M Brodsky; Taehyeon Kim; Janice M Juraska
Journal:  Dev Psychobiol       Date:  2017-05-31       Impact factor: 3.038

Review 8.  Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.

Authors:  Toshiharu Nagatsu; Ikuko Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-04       Impact factor: 3.575

9.  Differential effects of mineralocorticoid and angiotensin II on incentive and mesolimbic activity.

Authors:  Laura A Grafe; Loretta M Flanagan-Cato
Journal:  Horm Behav       Date:  2015-12-28       Impact factor: 3.587

10.  The V81M variant of tyrosine hydroxylase is associated with more severe freezing of gait in Parkinson's disease.

Authors:  Izel Tekin; Nurgul Carkaci-Salli; Mechelle M Lewis; Richard B Mailman; Xuemei Huang; Kent E Vrana
Journal:  Parkinsonism Relat Disord       Date:  2015-12-23       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.